Objective To compare key features of the new oral anticoagulants (NOACs)—dabigatran,
rivaroxaban, and apixaban—and to address questions that arise when comparing the …

Atrial fibrillation is a commonly encountered arrhythmia associated with increased risk for
thromboembolic events. Anticoagulation is necessary to decrease the risk of ischemic …

The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more
common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation …

Patients with atrial fibrillation (AF) who take direct oral anticoagulants (DOACs) face the risk
of intracranial hemorrhage (ICH), which can be serious and even life threatening, but the risk …

Atrial fibrillation (AF) is a common cardiac arrhythmia and it is associated with systemic
thromboembolism. Until recently, vitamin K antagonists (VKA) such as warfarin were the only …

Atrial fibrillation (AF) is a major cause of ischaemic stroke. The majority of these strokes can
be prevented by treatment with oral anticoagulation therapy. The advent of non-vitamin K …

Background: The comparative effectiveness of non-vitamin K antagonist oral anticoagulants
(NOACs) is uncertain, as they have not been compared directly in randomized trials …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …

Direct or new oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran
and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently …